Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Urinary Bladder Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Medulloblastoma 1Lung Neoplasms 1Leukemia, Hairy Cell 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma in Situ 1Breast Neoplasms 1

Interventions

Cyclophosphamide 15Temozolomide 11Vincristine 10Magnetic Resonance Spectroscopy 10Cisplatin 10Specimen Handling 8Radiotherapy 8Etoposide 8X-Rays 6Phantoms, Imaging 6Carboplatin 6Nuclear Medicine Department, Hospital 5Lomustine 5Radiation 4Platinum 4Methotrexate 4Irinotecan 4Filgrastim 4Biopsy 41,2-diaminocyclohexaneplatinum II citrate 4etoposide phosphate 3Thiotepa 3Nivolumab 3Granulocyte Colony-Stimulating Factor 3Celecoxib 3Bevacizumab 3Automobiles 3ulixertinib 2tipifarnib 2tazemetostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Medulloblastoma × Histamine Antagonists × 1 year × Clear all
NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡